Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 5/20 | 0.68 |
| ▸ | CNR2 | P34972 | 4/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | GPX4 | P36969 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.53 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.53 |
| ▸ | CACNB1 | Q02641 | 2/20 | 0.53 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.53 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL917195 | 0.79 | GPX4 (0.69) | GPX4CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL17281595 | 0.77 | GPX4 (0.68) | GPX4CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL24496176 | 0.77 | GPX4 (1.00) | GPX4CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL11892988 | 0.73 | ALDH1A1 (0.81) | CNR1CNR2ALDH1A1NPSR1KDM4E | |
| SCHEMBL16769444 | 0.72 | KMT2A (0.82) | ALDH1A1GPX4KMT2ACACNA2D1CACNA1B | |
| SCHEMBL24496402 | 0.72 | GPX4 (0.64) | GPX4CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL13309468 | 0.72 | KMT2A (0.82) | ALDH1A1GPX4KMT2ACACNA2D1CACNA1B | |
| SCHEMBL3298085 | 0.72 | DRD2 (0.47) | CNR1CNR2GPX4 | |
| SCHEMBL15266317 | 0.72 | MGLL (0.69) | CNR1CNR2GPX4CACNA2D1CACNA1B | |
| SCHEMBL17276651 | 0.71 | GPX4 (0.56) | GPX4CACNA2D1CACNA1BCACNB1CACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306087-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | claimed |
| US-20080306087-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
| US-20080306087-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
| US-20080306087-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
| EP-1915355-A1 | THERAPEUTIC AGENTS | AstraZeneca AB (SE) | 2008-04-30 | — | — | EP | disclosed |
| WO-2007018459-A1 | THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306087-A1 | Therapeutic Agents | NLN, BDNF, GAP43 | CNR1 173/4885CNR2 209/4885ALDH1A1 500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.